The Editor’s Roundtable: Diabetes Mellitus and Coronary Heart Disease

  • Author Footnotes
    ¶ Dr. Friedewald has no relevant financial relationships to disclose.
    Vincent E. Friedewald
    Correspondence
     Corresponding author: Tel: 512-264-1611; fax: 512-264-7034.
    Footnotes
    ¶ Dr. Friedewald has no relevant financial relationships to disclose.
    Affiliations
    Clinical Professor of Internal Medicine, University of Texas Health Sciences Center at Houston, Houston, Texas; Visiting Professor, University of Notre Dame, Notre Dame, Indiana
    Search for articles by this author
  • Author Footnotes
    Disclosure:Dr. Leiter has received research support and honoraria for speaking and consulting from AstraZeneca, Wilmington, Delaware; Eli Lilly, Indianapolis, Indiana; GlaxoSmithKline, Inc., Philadelphia, Pennsylvania, Merck/Schering Plough, North Wales, Pennsylvania; Pfizer, Inc., New York, New York; and sanofi aventis, Paris, France.
    Lawrence A. Leiter
    Footnotes
    Disclosure:Dr. Leiter has received research support and honoraria for speaking and consulting from AstraZeneca, Wilmington, Delaware; Eli Lilly, Indianapolis, Indiana; GlaxoSmithKline, Inc., Philadelphia, Pennsylvania, Merck/Schering Plough, North Wales, Pennsylvania; Pfizer, Inc., New York, New York; and sanofi aventis, Paris, France.
    Affiliations
    Head, Division of Endocrinology and Metabolism, St. Michael’s Hospital, Toronto, Ontario, Canada; Professor of Medicine and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
    Search for articles by this author
  • Author Footnotes
    ‡ Dr. McGuire has received research support and honoraria for speaking from Pfizer, Inc., New York, New York; honoraria for speaking and consulting from Takeda, Lincolnshire, Illinois; and research support from GlaxoSmithKline, Inc, Philadelphia, Pennsylvania.
    Darren K. McGuire
    Footnotes
    ‡ Dr. McGuire has received research support and honoraria for speaking from Pfizer, Inc., New York, New York; honoraria for speaking and consulting from Takeda, Lincolnshire, Illinois; and research support from GlaxoSmithKline, Inc, Philadelphia, Pennsylvania.
    Affiliations
    Associate, Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School at Dallas, Dallas, Texas
    Search for articles by this author
  • Author Footnotes
    § Dr. Nesto has received honoraria for speaking from GlaxoSmithKline, Inc., Philadelphia, Pennsylvania, and Lilly-Takeda, Lincolnshire, Illinois.
    Richard W. Nesto
    Footnotes
    § Dr. Nesto has received honoraria for speaking from GlaxoSmithKline, Inc., Philadelphia, Pennsylvania, and Lilly-Takeda, Lincolnshire, Illinois.
    Affiliations
    Chair, Department of Cardiovascular Medicine, Lahey Clinic Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts
    Search for articles by this author
  • Author Footnotes
    ∥ Dr. Roberts has received honoraria for speaking from AstraZeneca, Wilmington, Delaware; Merck, Whitehouse Station, New Jersey; Merck/Schering Plough, North Wales, New Jersey; Novartis, East Hanover, New Jersey; Pfizer, New York, New York; Schering Plough, Kenilworth, New Jersey.
    William C. Roberts
    Footnotes
    ∥ Dr. Roberts has received honoraria for speaking from AstraZeneca, Wilmington, Delaware; Merck, Whitehouse Station, New Jersey; Merck/Schering Plough, North Wales, New Jersey; Novartis, East Hanover, New Jersey; Pfizer, New York, New York; Schering Plough, Kenilworth, New Jersey.
    Affiliations
    Executive Director, Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas; Editor-in-Chief, The American Journal of Cardiology; and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, Texas
    Search for articles by this author
  • Author Footnotes
    Disclosure:Dr. Leiter has received research support and honoraria for speaking and consulting from AstraZeneca, Wilmington, Delaware; Eli Lilly, Indianapolis, Indiana; GlaxoSmithKline, Inc., Philadelphia, Pennsylvania, Merck/Schering Plough, North Wales, Pennsylvania; Pfizer, Inc., New York, New York; and sanofi aventis, Paris, France.
    ‡ Dr. McGuire has received research support and honoraria for speaking from Pfizer, Inc., New York, New York; honoraria for speaking and consulting from Takeda, Lincolnshire, Illinois; and research support from GlaxoSmithKline, Inc, Philadelphia, Pennsylvania.
    § Dr. Nesto has received honoraria for speaking from GlaxoSmithKline, Inc., Philadelphia, Pennsylvania, and Lilly-Takeda, Lincolnshire, Illinois.
    ∥ Dr. Roberts has received honoraria for speaking from AstraZeneca, Wilmington, Delaware; Merck, Whitehouse Station, New Jersey; Merck/Schering Plough, North Wales, New Jersey; Novartis, East Hanover, New Jersey; Pfizer, New York, New York; Schering Plough, Kenilworth, New Jersey.
    ¶ Dr. Friedewald has no relevant financial relationships to disclose.
      Patients with diabetes mellitus have 2 to 4 times greater risk for cardiac disease or stroke compared with the general population, and coronary heart disease is the most common cause of premature death in diabetic patients in the United States (US).
      • Merz C.N.B.
      • Buse J.B.
      • Tuncer D.
      • Twillman G.B.
      Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes.
      With the rapidly increasing incidence of obesity and type 2 diabetes in the US and globally, the prevalence of diabetes-related cardiovscular disease will continue to increase over the coming decades. Because the need for cardiologists to become more proactive in primary and secondary prevention in patients with diabetes is essential for these trends to be contained or perhaps even reversed, this Editor’s Roundtable explores the diagnosis and management of diabetes in patients with coronary heart disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Merz C.N.B.
        • Buse J.B.
        • Tuncer D.
        • Twillman G.B.
        Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes.
        J Am Coll Cardiol. 2002; 40: 1877-1881
        • Coutinho M.
        • Gerstein H.C.
        • Wang Y.
        • Yusuf S.
        The relationship between glucose and incident cardiovascular events.
        Diabetes Care. 1999; 22: 233-240
        • Nathan D.M.
        • Cleary P.A.
        • Backlund J.Y.
        • Genuth S.M.
        • Lachin J.M.
        • Orchard T.J.
        • Raskin P.
        • Zinman B.
        • Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group
        Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
        N Engl J Med. 2005; 353: 2643-2653
        • Hudson B.I.
        • Harja E.
        • Moser B.
        • Schmidt A.M.
        Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?.
        Arterioscler Thromb Vasc Biol. 2005; 25: 879-882
        • Park L.
        • Raman K.G.
        • Lee K.J.
        • Lu Y.
        • Ferran Jr, L.J.
        • Chow W.S.
        • Stern D.
        • Schmidt A.M.
        Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
        Nat Med. 1998; 4: 1025-1031
        • Cipollone F.
        • Iezzi A.
        • Fazia M.
        • Zucchelli M.
        • Pini B.
        • Currurullo C.
        • Cesare D.O.
        • Blasis G.D.
        • Muraro R.
        • Bei R.
        The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.
        Circulation. 2003; 108: 1070-1077
        • Schmidt A.M.
        • Stern D.M.
        RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.
        Trends Endocrinol Metab. 2000; 11: 368-375
        • Marx N.
        • Walcher D.
        • Raichle C.
        • Aleksic M.
        • Bach H.
        • Grüb H.
        • Hombach V.
        • Libby P.
        • Zieske A.
        • Homma S.
        • Strong J.
        C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro.
        Arterioscler Thromb Vasc Biol. 2004; 24: 540-545
        • Walcher D.
        • Aleksic M.
        • Jerg V.
        • Hombach V.
        • Zieske A.
        • Homma S.
        • Strong J.
        • Marx N.
        C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase.
        Diabetes. 2004; 53: 1664-1670
        • Ceriello A.
        Postprandial hyperglycemia and diabetes complications: is it time to treat?.
        Diabetes. 2005; 54: 1-7
        • Unger R.H.
        Lipotoxic diseases.
        Annu Rev Med. 2002; 53: 319-336
        • Unger R.H.
        • Orci L.
        Diseases of liporegulation: new perspective on obesity and related disorders.
        FASEB J. 2001; 15: 312-321
        • Unger R.H.
        • Orci L.
        Lipoapoptosis: its mechanism and its diseases.
        Biochim Biophys Acta. 2002; 1585: 202-212
        • McGarry J.D.
        Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes.
        Diabetes. 2002; 51: 7-18
        • Creager M.A.
        • Lüscher T.F.
        Diabetes and vascular disease.
        Circulation. 2003; 108: 1527-1532
        • Crall F.V.
        • Roberts W.C.
        The extramural and intramural coronary arteries in juvenile diabetes mellitus.
        Am J Cardiol. 1978; 64: 221-230
        • Waller B.F.
        • Palumbo P.J.
        • Lie J.T.
        • Roberts W.C.
        Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years.
        Am J Med. 1980; 69: 498-506
        • Das S.R.
        • Vaeth P.A.C.
        • Stanek H.G.
        • de Lemos J.A.
        • Dobbins R.L.
        • McGuire D.K.
        Under-diagnosis, increased coronary calcium and sub-optimal cardiovascular risk modification associated with diabetes mellitus in Dallas County: observations from the Dallas Heart Study.
        Am Heart J. 2006; 151: 1087-1093
        • Raggi P.
        • Shaw L.J.
        • Berman D.S.
        • Callister T.Q.
        Prognostic value of coronary artery calcium screening in subjects with and without diabetes.
        J Am Coll Cardiol. 2004; 43: 1663-1669
        • Olson J.C.
        • Edmundowicz D.
        • Becker D.J.
        • Kuller L.H.
        • Orchard T.J.
        Coronary calcium in adults with type I diabetes: a stronger correlate of clinical coronary artery disease in men than in women.
        Diabetes. 2000; 49: 1571-1578
        • Cipollone F.
        COX-2 and prostaglandins in atherosclerosis.
        Lupus. 2005; 14: 756-759
        • Cipollone F.
        • Rocca B.
        • Patrono C.
        Cyclooxygenase-2 expression and inhibition in atherothrombosis.
        Arterioscler Thromb Vasc Biol. 2004; 24: 246-255
        • Zuccollo A.
        • Shi C.
        • Mastroianni R.
        • Maitland-Tooland K.A.
        • Weistrob R.M.
        • Zang M.
        • Yu S.
        • Jiang B.
        • Oliver-Kranski J.M.
        • Cyatte A.J.
        • Corda S.
        The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
        Circulation. 2005; 112: 3001-3008
        • Steiner G.
        • Diabetes Atherosclerosis Intervention Study Investigators
        Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study.
        Lancet. 2001; 357: 905-910
        • Chung E.H.
        • Curran P.J.
        • Sivasankaran S.
        • Chauhan M.S.
        • Pyne C.T.
        • Piemonte T.C.
        • Gossman D.E.
        • Waters J.
        • Bilazarian S.
        • Raby K.
        • Riskala N.
        • Shoraki A.
        • Nesto R.W.
        Prevalence of metabolic syndrome in patients <45 years old with acute coronary syndrome presenting for emergent primary percutaneous intervention.
        J Am Coll Cardiol. 2006; 47 (Presented at ACC Annual Scientific Session 2006, Atlanta).: 216A
        • Haffner S.M.
        • Lehto S.
        • Ronnemaa T.
        • Pyorala K.
        • Laakso M.
        Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
        N Engl J Med. 1998; 339: 229-234
        • NCEP Expert Panel
        Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
        JAMA. 2001; 285: 2486-2497
        • Evans J.
        • Wang J.
        • Morris A.
        Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.
        BMJ. 2000; 321: 939-942
        • UK Prospective Diabetes Study (UKPDS) Group
        Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • McGuire D.K.
        • Emanuelsson H.
        • Granger C.B.
        • Ohman E.M.
        • Moliterno D.J.
        • White H.D.
        • Ardissino D.
        • Box J.W.
        • Califf R.M.
        • Topol E.J.
        • GUSTO-IIb Investigators
        Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes.
        Eur Heart J. 2000; 21: 1750-1758
        • McGuire D.K.
        • Newby L.K.
        • Bhapkar M.V.
        • Moliterno D.J.
        • Hochman J.S.
        • Klein W.
        • Weaver W.D.
        • Pfisterer M.
        • Dimas A.
        • Corbalan R.
        • Granger C.B.
        • Van de Werf F.
        • Topol E.J.
        • Califf R.M.
        • SYMPHONY and 2nd SYMPHONY Investigators
        Influence of diabetes mellitus and glycemic control strategies on clinical outcomes after acute coronary syndromes: findings from the SYMPHONY and 2ND SYMPHONY Studies.
        Am Heart J. 2004; 147: 246-252
        • Alexander C.M.
        • Landsman P.B.
        • Teutsch S.M.
        • Haffner S.M.
        NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.
        Diabetes. 2003; 52: 1210-1214
        • Keech A.
        • Simes R.J.
        • Barter P.
        • Best J.
        • Scott R.
        • Taskinen M.R.
        • Forder P.
        • Pillai A.
        • Davis T.
        • Glasziou P.
        • Drury P.
        • Kesaniemi Y.A.
        • Sullivan D.
        • Hunt D.
        • Colman P.
        • d’Emden M.
        • Whiting M.
        • Ehnholm C.
        • Laakso M.
        • FIELD Study Investigators
        Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
        Lancet. 2005; 366: 1849-1861
        • Taubert G.
        • Winkelmann B.R.
        • Schleiffer T.
        • März W.
        • Winkler R.
        • Gök R.
        • Klein B.
        • Schneider S.
        • Boehm B.O.
        Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography.
        Am Heart J. 2003; 145: 285-291
        • Saydah S.H.
        • Loria C.M.
        • Eberhardt M.S.
        • Brancati F.L.
        Subclinical states of glucose intolerance and risk of death in the U.S..
        Diabetes Care. 2001; 24: 447-453
        • Muhlestein J.B.
        • Anderson J.L.
        • Horne B.D.
        • Lavasani F.
        • Maycock C.A.A.
        • Bair T.L.
        • Pearson R.R.
        • Carlquist J.F.
        • Intermountain Heart Collaborative Study Group
        Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention.
        Am Heart J. 2003; 146: 351-358
        • Norhammar A.
        • Tenerz A.
        • Nilsson G.
        • Hamsten A.
        • Efendic S.
        • Rydén L.
        • Malmberg K.
        Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.
        Lancet. 2002; 359: 2140-2144
      1. American Diabetes Association Standards of Medical Care in Diabetes – 2006.
        Diabetes Care. 2006; 29: S4-S42
        • Beisswenger P.
        • Heine R.J.
        • Leiter L.A.
        • Moses A.
        • Tuomilehto J.
        Prandial glucose regulation in the glucose triad: emerging evidence and insights.
        Endocrine. 2004; 25: 195-202
        • Turner R.
        • Stratton I.
        • Horton V.
        • Manley S.
        • Zimmet P.
        • Mackay I.R.
        • Shattock M.
        • Bottazzo G.F.
        • Holman R.
        UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes.
        Lancet. 1997; 350: 1288-1293
        • Malmberg K.
        • DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group
        Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus.
        BMJ. 1997; 314: 1512-1515
      2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. A report of the Am Coll of Cardiol/Am Heart Assoc Task Force on Practice Guidelines (Committee to revise the 1999 guidelines). Bethesda, MD: American College of Cardiology, American Heart Association; 2004. Available at: http://www.guideline.gov/summary/summary.aspx?doc_id=5457&nbr=003734&string=STEMI. Accessed on May 1, 2006.

        • McGuire D.K.
        • Khera A.
        • de Lemos J.A.
        • Peterson E.D.
        • Warner J.J.
        • Parsons L.S.
        • Rogers W.J.
        • Canto J.G.
        • National Registry of Myocardial Infarctions Investigators
        Women with diabetes mellitus have the greatest reduction in mi mortality over the past decade: evaluation of 1,428,596 patients enrolled in the National Registry of Myocardial Infarction (NRMI) 2, 3, & 4 from 1994–2002.
        J Am Coll Cardiol. 2004; 43: 284A
        • Van den Berghe G.
        • Wouters P.
        • Weekers F.
        • Verwaest C.
        • Bruyninckx F.
        • Schetz M.
        • Vlasselaers D.
        • Ferdinande P.
        • Lauwers P.
        • Bouillon R.
        Intensive insulin therapy in critically ill patients.
        N Engl J Med. 2001; 345: 1359-1367
        • Malmberg K.
        • Rydén L.
        • Wedel H.
        • Birkeland K.
        • Bootsma A.
        • Dickstein K.
        • Efendic S.
        • Fisher M.
        • Hamsten A.
        • Herlitz J.
        • Hildebrandt P.
        • MacLeod K.
        • Laasko M.
        • Torp-Pedersen C.
        • Waldenström A.
        • DIGAMI 2 Investigators
        Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
        Eur Heart J. 2005; 26: 650-661
        • Malmberg K.
        • McGuire D.K.
        Diabetes and acute myocardial infarction: the role of insulin therapy.
        Am Heart J. 1999; 138: S381-S386
        • Ceremuzynski L.
        • Budaj A.
        • Czepiel A.
        • Burzykowski T.
        • Achremczyk P.
        • Smielak-Korombel W.
        • Maciejewicz J.
        • Dziubinska J.
        • Nartowicz E.
        • Kawka-Urbanek T.
        • Piotrowski W.
        • Hanzlik J.
        • Cieslinski A.
        • Kawecka-Jaszcz K.
        • Gessek J.
        • Wrabec K.
        Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial.
        Cardiovasc Drugs Ther. 1999; 13: 191-200
        • Svensson A.M.
        • McGuire D.K.
        • Abrahamsson P.
        • Dellborg M.
        Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events.
        Eur Heart J. 2005; 26: 1255-1261
        • Kahn R.
        • Buse J.
        • Ferrannini E.
        • Stern M.
        The metabolic syndrome: time for a critical appraisal.
        Diabetes Care. 2005; 28: 2289-2304
        • American Diabetes Association
        Standards of Medical Care in Diabetes.
        Diabetes Care. 2005; 28: S4-S36
        • The Heart Protection Study Investigators
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • Hitman G.A.
        • Neil H.A.W.
        • Livingston S.J.
        • Thomason J.
        • Mackness M.I.
        • Charlton-Menys V.
        • Fuller H.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • CDC Diabetes Cost-effectiveness Group
        Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
        JAMA. 2002; 287: 2542-2551
        • Gaede P.
        • Vedel P.
        • Larsen N.
        • Jensen G.V.
        • Parving H.H.
        • Pedersen O.
        Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
        N Engl J Med. 2003; 348: 383-393
        • UK Prospective Diabetes Study (UKPDS) Group
        Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • Grundy S.M.
        • Vega G.L.
        • McGovern M.E.
        • Tulloch B.R.
        • Kendall D.M.
        • Fitz-Patrick D.
        • Ganda O.P.
        • Rosenson R.S.
        • Buse J.B.
        • Robertson D.D.
        • Sheehan J.P.
        • Diabetes Multicenter Research Group
        Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
        Arch Intern Med. 2002; 162: 1568-1576
        • Taylor A.J.
        • Sullenberger L.E.
        • Hyun J.L.
        • Lee J.K.
        • Grace K.A.
        Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2.
        Circulation. 2004; 110: 3512-3517
        • UK Prospective Diabetes Study Group
        Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
        BMJ. 1998; 317: 703-713
        • Dickstein K.
        • Kjekshus J.
        Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial.
        Lancet. 2002; 360: 752-760
        • Schnell O.
        • Schafer O.
        • Kleybrink S.
        • Doering W.
        • Standl E.
        • Otter W.
        Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction.
        Diabetes Care. 2004; 27: 455-460
        • Abraira C.
        • Colwell J.A.
        • Nuttall F.Q.
        • Sawin C.T.
        • Nagel N.J.
        • Comstock J.P.
        • Emanuele N.V.
        • Levin S.R.
        • Henderson W.
        • Lee H.S.
        Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
        Diabetes Care. 1995; 18: 1113-1123
        • Prout T.E.
        • Knatterud G.L.
        • Meinert C.L.
        • Klimt C.R.
        The UGDP controversy.
        Diabetes. 1972; 21: 1035-1040
        • Misbin R.I.
        The phantom of lactic acidosis due to metformin in patients with diabetes.
        Diabetes Care. 2004; 27: 1791-1793
        • Inzucchi S.E.
        • Masoudi F.A.
        • Wang Y.
        • Kosiborod M.
        • Foody J.M.
        • Setaro J.F.
        • Havranek E.P.
        • Krumholz H.M.
        Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.
        Diabetes Care. 2005; 28: 1680-1689
        • Masoudi F.A.
        • Inzucchi S.E.
        • Wang Y.
        • Havranek E.P.
        • Foody J.M.
        • Krumholz H.M.
        Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
        Circulation. 2005; 111: 583-590
        • UK Prospective Diabetes Study (UKPDS) Group
        Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
        Lancet. 1998; 352: 854-865
        • Dormandy J.A.
        • Charbonnel B.
        • Eckland D.J.A.
        • Erdmann E.
        Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
        Lancet. 2005; 366: 1279-1289
        • Choi D.
        • Kim S.-K.
        • Choi S.-H.
        • Ko Y.-G.
        • Ahn C.-W.
        • Jang Y.
        • Lim S.-K.
        • Lee H.-C.
        • Cha B.-S.
        Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
        Diabetes Care. 2004; 27: 2654-2660
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        • Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
        Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Woodfield S.L.
        • Lundergan C.F.
        • Reiner J.S.
        • Greenhouse S.W.
        • Thompson M.A.
        • Rohrbeck S.C.
        • Deychak Y.
        • Simoons M.L.
        • Califf R.M.
        • Topol E.J.
        • Ross A.M.
        Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.
        J Am Coll Cardiol. 1996; 28: 1661-1669
        • Norhammar A.
        • Malmberg K.
        • Diderholm E.
        • Lagerqvist B.
        • Lindahl B.
        • Ryden L.
        • Wallentin L.
        Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
        J Am Coll Cardiol. 2004; 43: 585-591